GSK sues Lupin over Paxil generic plans; Sanofi to train UAE docs;

> GlaxoSmithKline ($GSK) and Apotex sued India-based Lupin over the latter's plans to sell copycat versions of the antidepressant Paxil in the U.S. Report

> Pharmacy benefits manager Express Scripts ($ESRX) agreed to pay $60 million to resolve federal and state claims that it participated in a kickback scheme to boost sales of the Novartis ($NVS) drug Exjade. Report

> GlaxoSmithKline landed in second place on a U.K. list of companies ranked by social media savvy. Report

> Sanofi ($SNY) inked a two-year deal to help train family doctors in the United Arab Emirates, in a variety of disease areas including cardiovascular and diabetes. Report

> The Centers for Medicare and Medicaid Services released a massive database on prescribing patterns among doctors treating Medicare patients. Report

> GlaxoSmithKline asked European regulators to approve a gene therapy to treat a rare immunodeficiency disease in children known as "bubble boy disease." Report

And Finally... The New York Times published an editorial backing Medicare negotiation powers on drug prices. Report (sub. req.)

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.